您好,欢迎来到佐思信息
全国服务热线:
400-009-0050
佐思信息专注支持企业决策
您当前的位置:首页>>研究报告>>药物综合

2016-2021年肾脏疾病治疗产品市场研究报告(2016版)
Renal Disease Treatments: Products and Therapies (Version 2016)

2016-2021年肾脏疾病治疗产品市场研究报告(2016版)
【报告编号】:No.25721
【发布时间】:2016-06
【关 键 字】:Renal Disease    肾脏疾病        
【报告页数】:218页
【报告价格】:电子版:6650美元
【交付方式】:Email发送或EMS快递
【订购热线】:


400-009-0050(全国24小时服务)
北京:010-82863481
上海:021-64871266 021-64872612

报告目录下载订购协议下载在线咨询

    专业、专注于为企业提供真正有价值的全球市场调查信息,是我们的使命。我们是中国第一家汇集全球众多行业研究机构研究成果的平台,致力于为企业决策提供最有效的市场资讯,特别是为中国企业了解和进入国际市场迈出第一步,提供全面的信息参考,我们跨越语言及时间的障碍,在信息爆炸的当下,努力为客户提供最有价值的全球产业资讯。我们公司也拥有独立的研究机构,聚焦于中国市场的研究,为国内外企业在中国市场大展宏图提供市场研究支持。

• 我们在全球的合作伙伴>>• 我们的研究中心>>

  • 英文摘要
  • 中文摘要
  • 索取简版报告
  • 药物综合行业的相关报告
DESCRIPTION
 
The U.S. market for kidney failure treatment will grow from $39.4 billion in 2016 to nearly $45.6 billion by 2021, with a compound annual growth rate (CAGR) of 3.0% for the period of 2016-2021.
 
This report provides:
An in-depth analysis of the market for kidney failure treatment products and services, forecasting growth and trends in various sectors.
Analyses of market trends, with data from 2015, 2016, and projections of compound annual growth rates (CAGRs) through 2021.
Detailed coverage of products and services including those for treating acute renal failure, chronic renal failure, and end-stage renal disease, the final phase of chronic kidney failure.
Specfic segmentation of the market into pharmaceuticals used to address the conditions associated with kidney failure (i.e., hypertension, diabetes, and anemia); hemodialysis and peritoneal dialysis products and services; and surgical procedures used to keep the end-stage kidney patient alive (i.e., surgeries to create vascular access sites for dialysis, and kidney transplantation).
Evaluation of the industry structure and dynamics, as well as technological developments.
Profiles of major players in the industry.
 
 
REPORT SCOPE
 
SCOPE OF REPORT
 
Five-year projections for market activity and value are provided. Treatment types and trends for acute and chronic kidney failure, pricing considerations for medications, dialysis products (dialysis machines, dialysates and dialyzers) and therapies, and surgical procedures, companies, industry structure, and participating companies are included in the study.
 
Breakdowns:
Therapeutic products.
Anemia.
Diabetic nephropathy.
Hyperkalemia.
Hypertension.
Renal replacement therapy.
Hemodialysis.
Intermittent hemodialysis.
Continuous renal replacement therapy (CRRT).
Peritoneal.
Continuous ambulatory peritoneal dialysis (CAPD).
Continuous cycling peritoneal dialysis (CCPD).
Renal transplantation.
 
Other related topics discussed include the diagnosis criteria, leading pharmaceutical companies and the competitive landscape. The market analysis is based on the regional, demographic and treatment options.
 
The report includes analysis of leading and emerging competitors in the current worldwide diagnostic market for kidney diseases. Profiles of manufacturers of leading products as well as biotechnology companies with products in development are discussed, along with their specific product strategies. Detailed profiles of current market leaders are included, as well as profiles of companies with innovative products poised to advance within the forecast period. Market figures are based on revenues at the manufacturers' level and are projected at 2016-dollar value. Inflation is not computed into projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products and projected changes in the prevalence of diagnosis for respective diseases. In addition, the report includes forecasts by product, product category and company from 2014 through 2021. The study is arranged to offer an overview of the diagnostic market accompanied by product, company and region.
 
Excluded from this report are treatments for the less-common kidney diseases, including polycystic kidney disease, Immunogloblin A (IgA) nephropathy, nephrotic syndrome and minimal change disease.. Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of sales change. Sales figures do not account for variation in local currencies. All market share data presented are on a global basis unless specifically noted.
 
ANALYST'S CREDENTIALS
Cheng-Yuk Lee is a life sciences researcher and engineer. He has experience in preclinical and translational medicine research in a pharmaceutical company and led several in vitro diagnostic assay developments as a senior scientist in multiple diagnostic companies. He received a dual bachelor of science degree in chemical engineering and biochemistry and subsequently completed his Ph.D. in chemical engineering and postdoctoral training. Prior to his professional career, he provided marketing research and strategic business planning for the Office of Corporate Relations at a public research university.
 
TABLE OF CONTENTS
 
CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY AND INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
 
CHAPTER 2 SUMMARY
SUMMARY TABLE THE U.S. MARKET FOR KIDNEY DISEASE TREATMENT, THROUGH 2021 ($ MILLIONS)
SUMMARY FIGURE THE U.S. MARKET FOR KIDNEY DISEASE TREATMENT, 2015-2021 ($ MILLIONS)
 
CHAPTER 3 KIDNEY DISEASE OVERVIEW
KIDNEY FUNCTION
RENAL DISEASE
SYMPTOMS
CLASSIFICATION OF KIDNEY INJURY AND DISEASE
TABLE 1 CRITERIA FOR KIDNEY INJURY/DISEASE
GLOMERULAR FILTRATION RATE (GFR)
LIMITATION OF CREATININE IN GFR MEASUREMENT
DECREASED ESTIMATED GFR
TABLE 2 STAGES OF CHRONIC KIDNEY DISEASE
RELATIONSHIP BETWEEN ACUTE KIDNEY INJURY AND CHRONIC KIDNEY DISEASE
FIGURE 1 RENAL STATUS ONE YEAR FOLLOWING DISCHARGE FROM AKI HOSPITALIZATION AMONG MEDICARE PATIENTS AGED 66+, 2010-2011 (% OF PATIENTS WITHOUT CKD BEFORE AKI)
FIGURE 2 POTENIAL OUTCOME OF ACUTE KIDNEY INJURY
CONNECTION BETWEEN CARDIOVASCULAR AND RENAL DISEASE
FIGURE 3 CARDIOVASCULAR DISEASE IN PATIENTS WITH OR WITHOUT CKD, 2012 (%)
EPIDEMIOLOGY
HOSPITALIZATION FROM KIDNEY DISEASE
FIGURE 4 TRENDS OF KIDNEY DISEASE INCIDENT RATE IN THE U.S.,1980-2005
THE ECONOMIC BUDREN AND COVERAGE OF KIDNEY DISEASE
MEDICARE'S ESRD PROGRAM
 
CHAPTER 4 ACUTE KIDNEY DISEASE OVERVIEW
FIGURE 5 CLASSIFICATION OF ACUTE KIDNEY INJURY
PRERENAL CAUSES
TABLE 3 COMMON MEDICATIONS THAT CAUSE ACUTE KIDNEY INJURY
INTRINSIC RENAL CAUSES
POSTRENAL CAUSES
EPIDEMIOLOGY
TABLE 4 RIFLE AND AKIN CRITERIA FOR DIAGNOSIS AND CLASSIFICATION OF AKI
DIAGNOSIS
FIGURE 6 TREATMENT FLOWCHART FOR ACUTE KIDNEY INJURY
NOVEL AKI BIOMARKER
HOSPITALIZATION IN PATIENTS WITH ACUTE KIDNEY DISEASE
FIGURE 7 NUMBER OF HOSPITALIZATIONS WITH ACUTE KIDNEY INJURY, 1979-2002
TABLE 5 CHARACTERISTICS OF MEDICARE PATIENTS AGED 66 AND ABOVE WITH AT LEAST ONE AKI HOSPITALIZATION: AGE, SEX, RACE, CKD, DM, BY YEAR, 2003-2012
AKI PREVALENCE
TABLE 6 NUMBER OF PATIENTS WITH AKI IN THE UNITED STATES BY AREA, THROUGH 2021
 
CHAPTER 5 TREATMENT FOR ACUTE KIDNEY DISEASE
PHARMACEUTICALS USED IN ACUTE KIDNEY INJURY
FUROSEMIDE
DOPAMINE
EPINEPHRINE
NOVEL PHARMACEUTICALS IN DEVELOPMENT
ACUTE RENAL REPLACEMENT THERAPY
INTERMITTENT HEMODIALYSIS
CONTINUOUS RENAL REPLACEMENT THERAPY
FIGURE 8 SCHEMATIC OF CONTINUOUS RENAL REPLACEMENT THERAPY
FIGURE 9 SCHEMATIC OF DIFFERENT TYPES OF CRRT
SUSTAINED LOW EFFICIENCY DIALYSIS
COMPARISON OF THE RENAL REPLACEMENT THERAPY
TABLE 7 CHARACTERISTICS OF DIALYSIS OPTIONS FOR TREATING AKI
INITIATION OF RENAL REPLACEMENT THERAPY
COST OF RRT
ECONOMICS OF AKI
TABLE 8 BREAKDOWN OF AVERAGE AKI TREATMENT COSTS BY SUBCATEGORY OF CARE ($)
THE U.S. MARKET FOR TREATING AKI
TABLE 9 U.S. MARKET FOR ACUTE KIDNEY INJURY TREATMENT, THROUGH 2021 ($ MILLIONS)
PHARMACEUTICALS IN AKI TREATMENT
RRT IN AKI TREATMENT
 
CHAPTER 6 CHRONIC KIDNEY DISEASE
OVERVIEW
EPIDEMIOLOGY OF RENAL DISEASE
TABLE 10 STAGES OF CHRONIC KIDNEY DISEASE: A CLINICAL ACTION PLAN
TABLE 11 AWARENESS, TREATMENT AND MEASURES OF CONTROL OF RISK FACTORS, 1998-2012 (% OF NHANES PARTICIPANTS)
CAUSE OF CHRONIC KIDNEY DISEASE
TABLE 12 CLASSIFICATION OF CHRONIC KIDNEY DISEASE BY PATHOLOGY, ETIOLOGY AND PREVALENCE IN PATIENTS WITH ESRD
MEDICATION CAUSES CHRONIC KIDNEY DISEASE AND RELATED COMPLICATIONS
TABLE 13 COMMON MEDICATION ASSOCIATED WITH CHRONIC KIDNEY DISEASE
ANEMIA
FIGURE 10 SCHEMATIC REPRESENTATION OF THE MECHANISMS UNDERLYING ANEMIA OF CKD
DIABETIC NEPHROPATHY
FIGURE 11 RECOGNIZED MOLECULAR MECHANISMS INVOLVED IN PATHOGENESIS OF DIABETIC KIDNEY DISEASE
ELECTROLYTE ABNORMALITY
Potassium Homeostasis
Hyperphosphatemia
FIGURE 12 MECHANISMS OF PHOSPHATE HOMEOSTASIS
HYPERTENSION
NUMBER OF INDIVIDUALS WITH CKD
FIGURE 13 CKD PATIENTS AWARE OF THEIR KIDNEY DISEASE, 2001-2012
TABLE 14 PATIENTS WITH CKD AND AWARNESS BY STAGE, 2012 (NUMBER AND %)
FIGURE 14 PREVALENCE OF CKD BY STAGE AMONG NHANES PARTICIPANTS, 1988-2012
FIGURE 15 TRENDS IN NUMBER OF PREVALENT ESRD CASES IN THE U.S. POPULATION BY AGE GROUP, 1996-2013 (THOUSANDS)
TABLE 15 NUMBER AND PERCENTAGE OF INCIDENT CASES OF HEMODIALYSIS (HD), PERITONEAL DIALYSIS (PD) AND TRANSPLANTATION IN THE U.S. POPULATION BY AGE, SEX, RACE, ETHNICITY AND PRIMARY CAUSE OF ESRD, 2013
TABLE 16 PREVALENCE OF CKD IN NHANES POPULATION WITHIN AGE, SEX, RACE/ETHNICITY AND RISK-FACTOR CATEGORIES, 1998-2012 (%)
HOSPITALIZATION AND MORTALITY IN PATIENTS WITH CHORNIC KIDNEY DISEASE
TABLE 17 UNADJUSTED AND ADJUSTED ALL-CAUSE HOSPITALIZATION RATES FOR MEDICARE PATIENTS AGED 66 AND OLDER BY CKD STATUS, 2012
FIGURE 16 ADJUSTED ALL-CAUSE HOSPITALIZATION RATES FOR MEDICARE PATIENTS AGED 66 AND OLDER BY CKD STATUS AND STAGE, 2012 (NO. OF ADMISSIONS)
FIGURE 17 ADJUSTED ALL-CAUSE HOSPITALIZATION RATES IN MEDICARE PATIENTS AGED 66 AND OLDER, BY RACE, CKD STATUS AND STAGE, 2012
FIGURE 18 UNADJUSTED AND ADJUSTED ALL-CAUSE MORTALITY RATE FOR MEDICARE PATIENTS
CKD TRENDS IN THE WORLD
TABLE 18 INCIDENCE OF ESRD BY COUNTRY, 2013 (PER MILLION POPULATION)
TABLE 19 PREVALENCE OF ESRD BY COUNTRY, 2013 (NO./%)
TABLE 20 TOP TEN COUNTRIES HAVING THE HIGHEST % RISE IN ESRD INCIDENCE RATE PLUS THE U.S., 2001 AND 2013
TABLE 21 FIVE COUNTRIES HAVING THE LARGEST % DECLINE IN ESRD INCIDENCE RATE, 2001 AND 2013
TABLE 22 PERCENTAGE OF INCIDENT ESRD PATIENTS DUE TO DIABETES BY COUNTRY, 2013 (%)
COSTS OF CHRONIC KIDNEY DISEASE
 
CHAPTER 7 PHARMACEUTICAL THERAPY STRATEGY AND MARKET FOR CHRONIC KIDNEY DISEASE
DRUG PRESCRIBING IN CHRONIC KIDNEY DISEASE
PHARMACEUTICAL THERAPIES
TABLE 23 PREVALENCE OF HYPERTENSION AND DYSLIPIDEMIA BY CKD STAGE (%)
TABLE 24 THE COMMONLY PRESCRIBED CLASS OF MEDICATION IN CHORNIC KIDNEY DISEASE PATIENTS (%)
ANTIHYPERTENSIVES
TABLE 25 RECOMMENDED ANTIHYPERTENSIVE AGENTS FOR PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERTENSION
ACE INHIBITORS
TABLE 26 COMMONLY PRESCRIBED ACE INHIBITORS: BRAND NAME, GENERIC NAME AND MANUFACTURER
ANGIOTENSIN RECEPTOR BLOCKERS
TABLE 27 COMMONLY PRESCRIBED ANGIOTENSIN RECEPTOR BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER
BETA BLOCKERS
TABLE 28 COMMONLY PRESCRIBED BETA BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER
CALCIUM CHANNEL BLOCKERS
TABLE 29 COMMONLY PRESCRIBED CALCIUM CHANNEL BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER
DIRECT RENIN INHIBITORS
ANTIHYPERKALEMIA
NOVEL DEVELOPMENT FOR TREATING HYPERKALEMIA
Patiromer
Sodium Zirconium Cyclosilicate
TABLE 30 LIST OF ANTIHYPERKALEMIA MEDICATION IN DEVELOPMENT: BRAND NAME, GENERIC NAME, MANUFACTURER AND CLINICAL STAGE
ANTIHYPERPHOSPHATEMIA
TABLE 31 COMMONLY PRESCRIBED PHOSPHATE BINDER: BRAND NAME, GENERIC NAME AND MANUFACTURER
CHOLESTEROL MANAGEMENT MEDICATIONS 95
STATINS 95
TABLE 32 COMMONLY PRESCRIBED STATIN: BRAND NAME, GENERIC NAME AND MANUFACTURER
BILE ACID SEQUESTRANTS
TABLE 33 COMMONLY PRESCRIBED BILE ACID SEQUESTRANTS: BRAND NAME, GENERIC NAME AND MANUFACTURER
CHOLESTEROL ABSORPTION INHIBITORS
FIBRATES
TABLE 34 COMMONLY PRESCRIBED FIBRATES: BRAND NAME, GENERIC NAME AND MANUFACTURER
NIACIN
COMBINATION MEDICATIONS
DIURETICS
THIAZIDE DIURETICS
LOOP DIURETICS
POTASSIUM-SPARING DIURETICS
TABLE 35 COMMONLY PRESCRIBED DIURETICS: BRAND NAME, GENERIC NAME AND MANUFACTURER
ERYTHROPOIESIS-STIMULATING AGENTS
TABLE 36 COMMONLY PRESCRIBED ERYTHROPOIESIS-STIMULATING AGENTS: BRAND NAME, GENERIC NAME AND MANUFACTURER
BIOSIMILAR DEVELOPMENT IN EPOGEN
SAFETY CONCERN FROM USING ERYTHROPOIESIS-STIMULATING AGENTS
NOVEL THERAPEUTIC DEVELOPMENT FOR RED BLOOD CELL STIMULATION
Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitors
TABLE 37 LIST OF HIF-PH INHIBITORS IN THE DEVELOPMENT: MANUFACTURER AND RESPECTIVE CLINICAL STAGE
Gene Therapy
IRON THERAPY
TABLE 38 COMMONLY PRESCRIBED IRON SUPPLEMENT: BRAND NAME, GENERIC NAME AND MANUFACTURER
GLUCOSE MANAGEMENT
TABLE 39 COMMONLY PRESCRIBED GLUCOSE MANAGEMENT: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 40 LIST OF NOVEL AGENT FOR TREATING DIABETIC NEPHROPATHY: MANUFACTURER AND RESPECTIVE CLINICAL STAGE
OTHER
TABLE 41 COMMONLY PRESCRIBED MEDICATION FOR CHRONIC KIDNEY DISEASE: BRAND NAME, GENERIC NAME AND MANUFACTURER
HORMONES
ACTIVE VITAMIN D
CALCIUM-LOWERING DRUGS
ADDITIONAL MEDICATIONS FOR DIALYSIS PATIENTS
Heparin
Citrate Anticoagulant
MEDICATIONS FOR CKD PATIENTS ON PERITONEAL DIALYSIS
INTRAPERITONEAL DOSING OF MEDICATIONS
DRUGS USED IN CONJUNCTION WITH KIDNEY TRANSPLANTATION
INDUCTION DRUGS
IMMUNOSUPPRESSANT AGENTS FOR KIDNEY TRANSPLANT
FIGURE 19 IMMUNOSUPPRESSION USE IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
TABLE 42 COMMONLY PRESCRIBED IMMUNOSUPPRESSANT DRUGS: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 43 IMMUNOSUPPRESSION MAINTENANCE REGIMEN AT DISCHARGE AND 1 YEAR AFTER TRANSPLANT, 2006
TABLE 44 IMMUNOSUPPRESSION DRUG USE, INDUCTION DRUGS, AT DISCHARGE, AT ONE YEAR POSTTRANSPLANT, 2005 AND 2006 (%)
BARRIERS TO ADHERENCE IN CHRONIC KIDNEY DISEASE
TABLE 45 FACTOR LINKED WITH NONCOMPLIANCE IN CHRONIC DISEASE
COSTS
TABLE 46 COSTS OF COMMONLY USED PRESCRIPTION DRUGS FOR TREATING RENAL FAILURE AND ASSOCIATED DISEASES
MARKET ANALYSIS OF PHARMACEUTICAL THERAPY FOR CHRONIC KIDNEY DISEASE
TABLE 47 THE U.S. MARKET FOR PHARMACEUTICALS USED IN CHRONIC KIDNEY DISEASE TREATMENT BY TYPE, THROUGH 2021 ($ MILLIONS)
THE MARKET FOR PHARMACEUTICALS USED IN CHRONIC KIDNEY DISEASE MANAGEMENT
THE MARKET FOR PHARMACEUTICALS USED IN KIDNEY DIALYSIS
TABLE 48 COMMON DRUG CLASSES USED BY PART D-ENROLLED DIALYSIS PATIENTS, BY PERCENTAGE OF PATIENTS, DRUG CLASS, 2013 (%)
TABLE 49 COMPARISON OF 2008 AND 2012-BASED ESRD MARKET BASKET COST CATEGORIES AND WEIGHTS
THE MARKET FOR PHARMACEUTICALS USED IN KIDNEY TRANSPLANTATION
COMPREHENSIVE IMMUNOSUPPRESSIVE DRUG COVERAGE FOR KIDNEY TRANSPLANT PATIENTS ACT OF 2013
 
CHAPTER 8 MARKET OF RENAL REPLACEMENT PRODUCTS AND SURGICAL PROCEDURES FOR END STAGE RENAL DISEASE
DIALYSIS OVERVIEW
FIGURE 20 MECHANISMS OF SOLUTE REMOVAL IN DIALYSIS
FIGURE 21 TRENDS IN THE NUMBER OF INCIDENT CASES OF ESRD IN THE U.S. POPULATION BY MODALITY, 1980-2012 (THOUSANDS)
TABLE 50 MARKET SHARE OF OVERALL DIALYSIS PRODUCTS, 2014 (%)
HEMODIALYSIS
FIGURE 22 SCHEMATIC OF THE HEMODIALYSIS MEMBRANE
MODES OF HEMODIALYSIS
Hemofiltration
Hemodiafiltration
HEMODIALYSIS SYSTEM
FIGURE 23 SCHEMATIC OF TYPICAL HEMODIALYSIS SYSTEM
MEASURING DIALYZER PERFORMANCE
DIALYZER REUSE
DIALYSATE
Sodium Citrate-Containing Dialysate
TABLE 51 DIALYSATE PRODUCTS FOR HD, PD AND CRRT
HOME HEMODIALYSIS
Novel Development in Home Hemodialysis Systems
PERITONEAL DIALYSIS
MODES OF PERITONEAL DIALYSIS
Continuous Ambulatory Peritoneal Dialysis
FIGURE 24 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS
Continuous Cycler-Assisted Peritoneal Dialysis
Nocturnal Intermittent Peritoneal Dialysis
Tidal Peritoneal Dialysis
Dialysate for PD
PERITONEAL DIALYSIS EQUIPMENT MANUFACTURERS
TABLE 52 PERITONEAL DIALYSIS SYSTEMS, TYPE AND MANUFACTURER
TABLE 53 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY MANUFACTURER, 2014 (%)
CONTINUOUS RENAL REPLACEMENT THERAPIES
SLOW CONTINUOUS ULTRAFILTRATION
CONTINUOUS VENO-VENOUS HEMOFILTRATION
CONTINUOUS VENO-VENOUS HEMODIALYSIS
CONTINUOUS VENO-VENOUS HEMODIAFILTRATION
THE U.S. MARKET FOR RENAL REPLACEMENT TREATMENT
TABLE 54 THE U.S. MARKET FOR ESRD TREATMENT BY TYPE, THROUGH 2021 ($ MILLIONS)
TABLE 55 THE U.S. ESRD POPULATION BY TREATMENT TYPE, 2010-2021 (NUMBER)
TABLE 56 THE U.S. ESRD POPULATION BY TREATMENT TYPE, 2010-2021 (PERCENTAGE OF DIALYSIS POPULATION)
THE MARKET OF HEMODIALYSIS
THE MARKET OF PERITONEAL DIALYSIS
DIALYSIS EQUIPMENT COSTS
TABLE 57 COSTS FOR COMMON DIALYSIS EQUIPMENT, HD, PD AND CRRT ($)
TABLE 58 MARKET SHARE OF HEMODIALYSIS PRODUCTS, 2014 (%)
TABLE 59 COMMERICAL DIALYSIS SYSTEMS AND MANUFACTURERS (HD, PD, CRRT)
THE U.S. MARKET FOR DIALYSIS SYSTEMS AND MAJOR CONSUMABLES
DIALYSIS MACHINES
TABLE 60 THE U.S. MARKET FOR DIALYSIS SYSTEMS BY TYPE, THROUGH 2021 ($ MILLIONS)
CONSUMABLES
TABLE 61 THE U.S. MARKET FOR MAJOR DIALYSIS CONSUMABLES BY TYPE, THROUGH 2021 ($ MILLIONS)
Dialyzers
Dialysate
DIALYSIS SERVICES
TABLE 62 DIALYSIS PATIENTS COUNTS BY UNIT AFFILIATION, 2010-2013 (NO./%)
TABLE 63 DIALYSIS CENTER IN THE U.S., 2010-2013 (UNITS/%)
MEDICARE'S PAYMENT SYSTEM FOR ESRD TREATMENT 151
NOVEL KIDNEY TREATMENT IN DEVELOPMENT 152
FIGURE 25 SCHEMATIC FOR ARTIFICIAL KIDNEY
PORTABLE, CARTRIDGE-BASED HEMODIALYSIS DEVICE
WEARABLE PERITONEAL DIALYSIS DEVICE
 
CHAPTER 9 SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT
VASCULAR ACCESS PROCEDURES
AV FISTULA
FIGURE 26 FOREARM AV FISTULA
AV GRAFT
FIGURE 27 AV GRAFT
VENOUS CATHETER
FIGURE 28 VENOUS CATHETER
FIGURE 29 TRENDS IN VASCULAR ACCESS TYPE USE AMONG ESRD PREVALENT PATIENTS, 2003-2014
TABLE 64 DISTRIBUTION OF TYPE OF VASCULAR ACCESS IN USE AMONG PREVALENT HEMODIALYSIS PATIENTS IN 2013, FROM CROWNWEB DATA, DECEMBER 2013
ACCESS REPLACEMENT AND REPAIR
VASCULAR ACCESS MARKET BY TYPE
PERITONEAL DIALYSIS CATHETER
FIGURE 30 TENCKHOFF CATHETERS
PD CATHETERIZATION COSTS
KIDNEY TRANSPLANT
DECEASED DONORS
LIVING DONORS
THE TRANSPLANT PROCEDURE
Donor
Recipient
Compatibility
Post Surgery
WAITING LIST FOR KIDNEY TRANSPLANTATION
FIGURE 31 PERCENTAGE OF DIALYSIS PATIENTS WAIT-LISTED AND UNADJUSTED KIDNEY TRANSPLANT RATES, 1996-2013 (%)
FIGURE 32 PERCENTAGE OF INCIDENT PATIENTS BEING WAIT-LISTED OR RECEIVING A KIDNEY TRANSPLANT WITHIN ONE YEAR OF ESRD INITIATION BY AGE, 1996-2012 (%)
TABLE 65 UNADJUSTED KIDNEY TRANSPLANT RATES, ALL DONOR TYPES BY AGE, SEX, RACE AND PRIMARY CAUSE OF ESRD, PER 100 DIALYSIS PATIENT YEARS, 2004-2013
FIGURE 33 NUMBER OF KIDNEY TRANSPLANTS, 1996-2013 (THOUSANDS)
FIGURE 34 DATA ON AGE, SEX, RACE, AND PRIMARY CAUSE OF DISEASE AMONG KIDNEY TRANSPLANT, 1998-2012
SURVIVAL IN POST TRANSPLANTATION
FIGURE 35 OUTCOMES IN ADULT KIDNEY TRANSPLANT RECIPIENTS: A) DECEASED DONOR, B) LIVING DONOR
ECONOMICS OF KIDNEY TRANSPLANT
FIGURE 36 MEDICARE COVERAGE AMONG KIDNEY TRANSPLANT RECIPIENTS (%)
THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN TREATING END STAGE RENAL DISEASE
TABLE 66 VASCULAR ACCESS USE AT HEMODIALYSIS INITIATION (%)
TABLE 67 THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT BY TYPE, THROUGH 2021 ($ MILLIONS)
TABLE 68 ESTIMATED U.S. AVERAGE BILLED CHARGES PER ORGAN TRANSPLANT, 2011 ($ THOUSANDS)
 
CHAPTER 10 INDUSTRY STRUCTURE
PHARMACEUTICALS MANUFACTURERS
DIALYSIS EQUIPMENT MAKERS
MANUFACTURERS OF DIALYSIS CONSUMABLES
THERAPIES
DIALYSIS
SURGERY
NONPROFIT ORGANIZATION PROFILES
ESRD NETWORK PROGRAM
ORGAN PROCUREMENT AND TRANSPLANTATION NETWORK
NATIONAL KIDNEY FOUNDATION
 
COMPANY PROFILES
ABBVIE BIOTHERAPEUTICS CORP.
ACCELERON PHARMA INC.
ACTAVIS PHARMA INC.
AKEBIA THERAPEUTICS
FIGURE 37 VADADUSTAT CLINICAL DEVELOPMENT
AM-PHARMA
AMAG PHARMACEUTICALS
AMERICAN REGENT INC.
AMERICAN RENAL ASSOCIATES INC.
AMERICAN VASCULAR DIALYSIS ACCESS CENTERS
AMGEN
ARDELYX
FIGURE 38 ARDELYX PIPELINE OVERVIEW
ASAHI KASEI KURARAY MEDICAL CO.
ASTELLAS PHARMA U.S. INC.
ASTRAZENECA PLC
AWAK TECHNOLOGIES INC.
B.BRAUN MEDICAL INC.
BARD ACCESS SYSTEMS INC.
BAXTER INTERNATIONAL
BAYER PHARMA AG
BOEHRINGER INGELHEIM
BRISTOL-MYERS SQUIBB
BIOCAD
CANTEL MEDICAL
CENTERS FOR DIALYSIS CARE
CHEMOCENTRYX INC.
CHONG KUN DANG PHARMACEUTICAL CORP.
CONCERT PHARMACEUTICALS INC.
DAVITA INC.
DIALYSIS CLINIC INC. (DCI)
DIVERSIFIED SPECIALTY INSTITUTES (DSI)
ELI LILLY AND CO.
FIBROGEN INC.
FIGURE 39 ROXADUSTAT DEVELOPMENT TIMELINE
FRESENIUS MEDICAL CARE (FMC)
GENENTECH INC.
GENKYOTEX INNOVATION SAS
GLAXOSMITHKLINE
HOSPIRA INC.
INCYTE CORP.
JANSSEN PHARMACEUTICALS
KERYX BIOPHARMACEUTICALS
KIDNEY CENTER INC.
KRINGLE PHARMACEUTICAL
KYOWA HAKKO KIRIN CO.
LIBERTY DIALYSIS
MAQUET CARDIOVASCULAR
MEDCOMP
MEDGENICS INC.
MEDICINES CO.
MERCK & CO.
MYLAN INC.
NAVILYST MEDICAL
NEPHROGENEX INC.
NIPRO CORP.
NORTHWEST KIDNEY CENTERS
NOVARTIS PHARMACEUTICALS
NOVO NORDISK A/S
NOXXON PHARMA A/G
FIGURE 40 NOXXON PIPELINE OVERVIEW
NXSTAGE MEDICAL
OUTSET MEDICAL INC.
PAR PHARMACEUTICAL INC.
PANGEN BIOTECH
PFIZER PHARMACEUTICAL
PROMETHEUS LABORATORIES INC.
RENAL RESEARCH INSTITUTE (RRI)
RELYPSA, INC
RENAL VENTURES MANAGEMENT LLC
ROCHE HOLDING A/G (F. HOFFMANN-LA ROCHE LTD.)
ROCKWELL MEDICAL TECHNOLOGIES
QUANTA FLUID SOLUTION LTD
SANOFI-AVENTIS
SANDOZ INTERNATIONAL GMBH
SATELLITE HEALTHCARE/WELLBOUND
SHIRE PHARMACEUTICALS GROUP
TAKEDA PHARMACEUTICALS
TEVA PHARMACEUTICALS USA
THRASOS INNOVATION
TORAY INDUSTRIES INC.
TRANSVIVO
UCB
U.S. RENAL CARE INC. (USRC)
VASCULAR ACCESS CENTERS
VASCULAR PHARMACEUTICALS
VIFOR PHARMA LTD.
ZS PHARMA INC.
 
LIST OF TABLES
SUMMARY TABLE THE U.S. MARKET FOR KIDNEY DISEASE TREATMENT, THROUGH 2021 ($ MILLIONS)
TABLE 1 CRITERIA FOR KIDNEY INJURY/DISEASE
TABLE 2 STAGES OF CHRONIC KIDNEY DISEASE
TABLE 3 COMMON MEDICATIONS THAT CAUSE ACUTE KIDNEY INJURY
TABLE 4 RIFLE AND AKIN CRITERIA FOR DIAGNOSIS AND CLASSIFICATION OF AKI
TABLE 5 CHARACTERISTICS OF MEDICARE PATIENTS AGED 66 AND ABOVE WITH AT LEAST ONE AKI HOSPITALIZATION: AGE, SEX, RACE, CKD, DM, BY YEAR, 2003-2012
TABLE 6 NUMBER OF PATIENTS WITH AKI IN THE UNITED STATES BY AREA, THROUGH 2021
TABLE 7 CHARACTERISTICS OF DIALYSIS OPTIONS FOR TREATING AKI
TABLE 8 BREAKDOWN OF AVERAGE AKI TREATMENT COSTS BY SUBCATEGORY OF CARE ($)
TABLE 9 U.S. MARKET FOR ACUTE KIDNEY INJURY TREATMENT, THROUGH 2021 ($ MILLIONS)
TABLE 10 STAGES OF CHRONIC KIDNEY DISEASE: A CLINICAL ACTION PLAN
TABLE 11 AWARENESS, TREATMENT AND MEASURES OF CONTROL OF RISK FACTORS, 1998-2012 (% OF NHANES PARTICIPANTS)
TABLE 12 CLASSIFICATION OF CHRONIC KIDNEY DISEASE BY PATHOLOGY, ETIOLOGY AND PREVALENCE IN PATIENTS WITH ESRD
TABLE 13 COMMON MEDICATION ASSOCIATED WITH CHRONIC KIDNEY DISEASE
TABLE 14 PATIENTS WITH CKD AND AWARNESS BY STAGE, 2012 (NUMBER AND %)
TABLE 15 NUMBER AND PERCENTAGE OF INCIDENT CASES OF HEMODIALYSIS (HD), PERITONEAL DIALYSIS (PD) AND TRANSPLANTATION IN THE U.S. POPULATION BY AGE, SEX, RACE, ETHNICITY AND PRIMARY CAUSE OF ESRD, 2013
TABLE 16 PREVALENCE OF CKD IN NHANES POPULATION WITHIN AGE, SEX, RACE/ETHNICITY AND RISK-FACTOR CATEGORIES, 1998-2012 (%)
TABLE 17 UNADJUSTED AND ADJUSTED ALL-CAUSE HOSPITALIZATION RATES FOR MEDICARE PATIENTS AGED 66 AND OLDER BY CKD STATUS, 2012
TABLE 18 INCIDENCE OF ESRD BY COUNTRY, 2013 (PER MILLION POPULATION)
TABLE 19 PREVALENCE OF ESRD BY COUNTRY, 2013 (NO./%)
TABLE 20 TOP TEN COUNTRIES HAVING THE HIGHEST % RISE IN ESRD INCIDENCE RATE PLUS THE U.S., 2001 AND 2013
TABLE 21 FIVE COUNTRIES HAVING THE LARGEST % DECLINE IN ESRD INCIDENCE RATE, 2001 AND 2013
TABLE 22 PERCENTAGE OF INCIDENT ESRD PATIENTS DUE TO DIABETES BY COUNTRY, 2013 (%)
TABLE 23 PREVALENCE OF HYPERTENSION AND DYSLIPIDEMIA BY CKD STAGE (%)
TABLE 24 THE COMMONLY PRESCRIBED CLASS OF MEDICATION IN CHORNIC KIDNEY DISEASE PATIENTS (%)
TABLE 25 RECOMMENDED ANTIHYPERTENSIVE AGENTS FOR PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERTENSION
TABLE 26 COMMONLY PRESCRIBED ACE INHIBITORS: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 27 COMMONLY PRESCRIBED ANGIOTENSIN RECEPTOR BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 28 COMMONLY PRESCRIBED BETA BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 29 COMMONLY PRESCRIBED CALCIUM CHANNEL BLOCKERS: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 30 LIST OF ANTIHYPERKALEMIA MEDICATION IN DEVELOPMENT: BRAND NAME, GENERIC NAME, MANUFACTURER AND CLINICAL STAGE
TABLE 31 COMMONLY PRESCRIBED PHOSPHATE BINDER: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 32 COMMONLY PRESCRIBED STATIN: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 33 COMMONLY PRESCRIBED BILE ACID SEQUESTRANTS: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 34 COMMONLY PRESCRIBED FIBRATES: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 35 COMMONLY PRESCRIBED DIURETICS: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 36 COMMONLY PRESCRIBED ERYTHROPOIESIS-STIMULATING AGENTS: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 37 LIST OF HIF-PH INHIBITORS IN THE DEVELOPMENT: MANUFACTURER AND RESPECTIVE CLINICAL STAGE
TABLE 38 COMMONLY PRESCRIBED IRON SUPPLEMENT: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 39 COMMONLY PRESCRIBED GLUCOSE MANAGEMENT: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 40 LIST OF NOVEL AGENT FOR TREATING DIABETIC NEPHROPATHY: MANUFACTURER AND RESPECTIVE CLINICAL STAGE
TABLE 41 COMMONLY PRESCRIBED MEDICATION FOR CHRONIC KIDNEY DISEASE: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 42 COMMONLY PRESCRIBED IMMUNOSUPPRESSANT DRUGS: BRAND NAME, GENERIC NAME AND MANUFACTURER
TABLE 43 IMMUNOSUPPRESSION MAINTENANCE REGIMEN AT DISCHARGE AND 1 YEAR AFTER TRANSPLANT, 2006
TABLE 44 IMMUNOSUPPRESSION DRUG USE, INDUCTION DRUGS, AT DISCHARGE, AT ONE YEAR POSTTRANSPLANT, 2005 AND 2006 (%)
TABLE 45 FACTOR LINKED WITH NONCOMPLIANCE IN CHRONIC DISEASE
TABLE 46 COSTS OF COMMONLY USED PRESCRIPTION DRUGS FOR TREATING RENAL FAILURE AND ASSOCIATED DISEASES
TABLE 47 THE U.S. MARKET FOR PHARMACEUTICALS USED IN CHRONIC KIDNEY DISEASE TREATMENT BY TYPE, THROUGH 2021 ($ MILLIONS)
TABLE 48 COMMON DRUG CLASSES USED BY PART D-ENROLLED DIALYSIS PATIENTS, BY PERCENTAGE OF PATIENTS, DRUG CLASS, 2013 (%)
TABLE 49 COMPARISON OF 2008 AND 2012-BASED ESRD MARKET BASKET COST CATEGORIES AND WEIGHTS
TABLE 50 MARKET SHARE OF OVERALL DIALYSIS PRODUCTS, 2014 (%)
TABLE 51 DIALYSATE PRODUCTS FOR HD, PD AND CRRT
TABLE 52 PERITONEAL DIALYSIS SYSTEMS, TYPE AND MANUFACTURER
TABLE 53 PERITONEAL DIALYSIS EQUIPMENT MARKET SHARE BY MANUFACTURER, 2014 (%)
TABLE 54 THE U.S. MARKET FOR ESRD TREATMENT BY TYPE, THROUGH 2021 ($ MILLIONS)
TABLE 55 THE U.S. ESRD POPULATION BY TREATMENT TYPE, 2010-2021 (NUMBER)
TABLE 56 THE U.S. ESRD POPULATION BY TREATMENT TYPE, 2010-2021 (PERCENTAGE OF DIALYSIS POPULATION)
TABLE 57 COSTS FOR COMMON DIALYSIS EQUIPMENT, HD, PD AND CRRT ($)
TABLE 58 MARKET SHARE OF HEMODIALYSIS PRODUCTS, 2014 (%)
TABLE 59 COMMERICAL DIALYSIS SYSTEMS AND MANUFACTURERS (HD, PD, CRRT)
TABLE 60 THE U.S. MARKET FOR DIALYSIS SYSTEMS BY TYPE, THROUGH 2021 ($ MILLIONS)
TABLE 61 THE U.S. MARKET FOR MAJOR DIALYSIS CONSUMABLES BY TYPE, THROUGH 2021 ($ MILLIONS)
TABLE 62 DIALYSIS PATIENTS COUNTS BY UNIT AFFILIATION, 2010-2013 (NO./%)
TABLE 63 DIALYSIS CENTER IN THE U.S., 2010-2013 (UNITS/%)
TABLE 64 DISTRIBUTION OF TYPE OF VASCULAR ACCESS IN USE AMONG PREVALENT HEMODIALYSIS PATIENTS IN 2013, FROM CROWNWEB DATA, DECEMBER 2013
TABLE 65 UNADJUSTED KIDNEY TRANSPLANT RATES, ALL DONOR TYPES BY AGE, SEX, RACE AND PRIMARY CAUSE OF ESRD, PER 100 DIALYSIS PATIENT YEARS, 2004-2013
TABLE 66 VASCULAR ACCESS USE AT HEMODIALYSIS INITIATION (%)
TABLE 67 THE U.S. MARKET FOR SURGICAL PROCEDURES USED IN RENAL FAILURE TREATMENT BY TYPE, THROUGH 2021 ($ MILLIONS)
TABLE 68 ESTIMATED U.S. AVERAGE BILLED CHARGES PER ORGAN TRANSPLANT, 2011 ($ THOUSANDS)
 
LIST OF FIGURES
SUMMARY FIGURE THE U.S. MARKET FOR KIDNEY DISEASE TREATMENT, 2015-2021 ($ MILLIONS)
FIGURE 1 RENAL STATUS ONE YEAR FOLLOWING DISCHARGE FROM AKI HOSPITALIZATION AMONG MEDICARE PATIENTS AGED 66+, 2010-2011 (% OF PATIENTS WITHOUT CKD BEFORE AKI)
FIGURE 2 POTENIAL OUTCOME OF ACUTE KIDNEY INJURY 20
FIGURE 3 CARDIOVASCULAR DISEASE IN PATIENTS WITH OR WITHOUT CKD, 2012 (%)
FIGURE 4 TRENDS OF KIDNEY DISEASE INCIDENT RATE IN THE U.S.,1980-2005
FIGURE 5 CLASSIFICATION OF ACUTE KIDNEY INJURY
FIGURE 6 TREATMENT FLOWCHART FOR ACUTE KIDNEY INJURY
FIGURE 7 NUMBER OF HOSPITALIZATIONS WITH ACUTE KIDNEY INJURY, 1979-2002
FIGURE 8 SCHEMATIC OF CONTINUOUS RENAL REPLACEMENT THERAPY
FIGURE 9 SCHEMATIC OF DIFFERENT TYPES OF CRRT
FIGURE 10 SCHEMATIC REPRESENTATION OF THE MECHANISMS UNDERLYING ANEMIA OF CKD
FIGURE 11 RECOGNIZED MOLECULAR MECHANISMS INVOLVED IN PATHOGENESIS OF DIABETIC KIDNEY DISEASE
FIGURE 12 MECHANISMS OF PHOSPHATE HOMEOSTASIS
FIGURE 13 CKD PATIENTS AWARE OF THEIR KIDNEY DISEASE, 2001-2012
FIGURE 14 PREVALENCE OF CKD BY STAGE AMONG NHANES PARTICIPANTS, 1988-2012
FIGURE 15 TRENDS IN NUMBER OF PREVALENT ESRD CASES IN THE U.S. POPULATION BY AGE GROUP, 1996-2013 (THOUSANDS)
FIGURE 16 ADJUSTED ALL-CAUSE HOSPITALIZATION RATES FOR MEDICARE PATIENTS AGED 66 AND OLDER BY CKD STATUS AND STAGE, 2012 (NO. OF ADMISSIONS)
FIGURE 17 ADJUSTED ALL-CAUSE HOSPITALIZATION RATES IN MEDICARE PATIENTS AGED 66 AND OLDER, BY RACE, CKD STATUS AND STAGE, 2012
FIGURE 18 UNADJUSTED AND ADJUSTED ALL-CAUSE MORTALITY RATE FOR MEDICARE PATIENTS
FIGURE 19 IMMUNOSUPPRESSION USE IN PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
FIGURE 20 MECHANISMS OF SOLUTE REMOVAL IN DIALYSIS
FIGURE 21 TRENDS IN THE NUMBER OF INCIDENT CASES OF ESRD IN THE U.S. POPULATION BY MODALITY, 1980-2012 (THOUSANDS)
FIGURE 22 SCHEMATIC OF THE HEMODIALYSIS MEMBRANE
FIGURE 23 SCHEMATIC OF TYPICAL HEMODIALYSIS SYSTEM
FIGURE 24 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS
FIGURE 25 SCHEMATIC FOR ARTIFICIAL KIDNEY
FIGURE 26 FOREARM AV FISTULA
FIGURE 27 AV GRAFT
FIGURE 28 VENOUS CATHETER
FIGURE 29 TRENDS IN VASCULAR ACCESS TYPE USE AMONG ESRD PREVALENT PATIENTS, 2003-2014
FIGURE 30 TENCKHOFF CATHETERS
FIGURE 31 PERCENTAGE OF DIALYSIS PATIENTS WAIT-LISTED AND UNADJUSTED KIDNEY TRANSPLANT RATES, 1996-2013 (%)
FIGURE 32 PERCENTAGE OF INCIDENT PATIENTS BEING WAIT-LISTED OR RECEIVING A KIDNEY TRANSPLANT WITHIN ONE YEAR OF ESRD INITIATION BY AGE, 1996-2012 (%)
FIGURE 33 NUMBER OF KIDNEY TRANSPLANTS, 1996-2013 (THOUSANDS)
FIGURE 34 DATA ON AGE, SEX, RACE, AND PRIMARY CAUSE OF DISEASE AMONG KIDNEY TRANSPLANT, 1998-2012
FIGURE 35 OUTCOMES IN ADULT KIDNEY TRANSPLANT RECIPIENTS: A) DECEASED DONOR, B) LIVING DONOR
FIGURE 36 MEDICARE COVERAGE AMONG KIDNEY TRANSPLANT RECIPIENTS (%)
FIGURE 37 VADADUSTAT CLINICAL DEVELOPMENT
FIGURE 38 ARDELYX PIPELINE OVERVIEW
FIGURE 39 ROXADUSTAT DEVELOPMENT TIMELINE
FIGURE 40 NOXXON PIPELINE OVERVIEW

关于我们|联系我们|常见问题|服务项目|购买流程
2005-2013 All rights reserved.京ICP备05069564号-4 京公网安备110108 02010359号
全国服务热线:400-009-0050北京:010-82863481上海:021-64871266

在线客服系统